Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study

European Journal of Cancer

Volumn 37, Issue 13, 2001, Pages 1624-1628

  Wagenaar, H C ^a,b   Pecorelli, S ^c   Mangioni, C ^d   Van der Burg, M E L ^e   Rotmensz, N ^b   Anastasopoulou, A ^b   Zola, P ^f   Veenhof, C H N ^g   Lacave, A J ^h   Neijt, J P ⁱ   Van Oosterom, A T ^j   Einhorn, N ^k   Vermorken, J B ^l  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF BRESCIA   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f MAURIZIANO HOSPITAL   (Italy)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k Department of Gynecological Oncology ^*  (Sweden)

^l ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Cervical cancer; Cisplatin; Mitomycin C; Phase II study

Indexed keywords

CISPLATIN; MITOMYCIN C;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISSEMINATED CANCER; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY DISEASE; LIVER DYSFUNCTION; MORTALITY; OUTPATIENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; MITOMYCIN; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0034891891     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00178-2     Document Type: Article

References (23)

1. Cisplatin in advanced cancer of the cervix: An update
2. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group study
3. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review
4. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix
5. Reporting results of cancer treatment
6. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapy agent
7. Cis-platinum and mitomycin-C in treatment of recurrent, metastatic, or residual uterine cervical cancer post radiation
8. Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy
9. A phase II evaluation of cisplatin, bleomycin, and mitomycin-C in patients with recurrent squamous cell carcinoma of the cervix
10. Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: A phase II study of the Northern California Oncology Group
11. Bleomycin, vincristine, mitomycin C, and cis-platinum in gynecologic squamous cell carcinomas: A high incidence of pulmonary toxicity
12. Chemotherapy for advanced and/or recurrent cervical cancer
13. Bleomycin, vincristine, mitomycin-C, and cisplatin in the management of gynecological squamous cell carcinomas
14. Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix
15. Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin
16. Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide
17. Cisplatin-based combination chemotherapy (BEMP) versus single agent cisplatin in disseminated squamous cell carcinoma of the uterine cervix (SCCUC): Mature data EORTC protocol 55863
18. Chemotherapy in advanced and recurrent cervical cancer. A review
19. Carcinoma of the uterine cervix: Current status and future directions
20. The role of paclitaxel in the management of patients with carcinoma of the cervix
21. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study
22. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
23. A randomised phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVb, recurrent or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study